Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Looks To Acquire Japanese Generics Maker Taiyo

This article was originally published in PharmAsia News

Executive Summary

Fresh off announcing it would swoop in to acquire U.S. specialty pharma Cephalon Inc. for $6.8 billion, the world's largest generics player Teva Pharmaceutical Industries is now looking to acquire Taiyo Pharmaceutical Industry Co., Japan's third largest generics maker, for roughly ¥40 billion ($493.6 million), according to reports. Teva, which already has a joint venture with Kowa Co., a mid-tier Japanese pharma, will likely use Taiyo mainly for manufacturing and Teva-Kowa for sales
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC078080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel